BlackRock’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,517,777
| Closed | -$72.6M | – | 5638 |
|
|
2025
Q3 | $72.6M | Sell |
1,517,777
-116,165
| -7% | -$3.22M | ﹤0.01% | 2277 |
|
|
2025
Q2 | $26.1M | Sell |
1,633,942
-158,266
| -9% | -$2.56M | ﹤0.01% | 2850 |
|
|
2025
Q1 | $27.3M | Sell |
1,792,208
-11,692
| -0.6% | -$187K | ﹤0.01% | 2753 |
|
|
2024
Q4 | $36.6M | Buy |
1,803,900
+50,553
| +3% | +$1.27M | ﹤0.01% | 2655 |
|
|
2024
Q3 | $45.1M | Buy |
1,753,347
+29,131
| +2% | +$486K | ﹤0.01% | 2531 |
|
|
2024
Q2 | $22.2M | Buy |
1,724,216
+1,228,841
| +248% | +$19.8M | ﹤0.01% | 2919 |
|
|
2024
Q1 | $11.3M | Buy |
495,375
+222,999
| +82% | +$7.86M | ﹤0.01% | 3288 |
|
|
2023
Q4 | $7.13M | Buy |
272,376
+259,693
| +2,048% | +$5.2M | ﹤0.01% | 3545 |
|
|
2023
Q3 | $356K | Sell |
12,683
-356
| -3% | -$10.4K | ﹤0.01% | 4514 |
|
|
2023
Q2 | $396K | Sell |
13,039
-103,448
| -89% | -$2.64M | ﹤0.01% | 4550 |
|
|
2023
Q1 | $2.19M | Buy |
116,487
+6,532
| +6% | +$108K | ﹤0.01% | 4015 |
|
|
2022
Q4 | $1.12M | Sell |
109,955
-88,819
| -45% | -$1.43M | ﹤0.01% | 4376 |
|
|
2022
Q3 | $5.23M | Sell |
198,774
-53,287
| -21% | -$1.94M | ﹤0.01% | 3737 |
|
|
2022
Q2 | $11.4M | Buy |
252,061
+8,670
| +4% | +$684K | ﹤0.01% | 3435 |
|
|
2022
Q1 | $23.9M | Buy |
243,391
+3,844
| +2% | +$360K | ﹤0.01% | 3060 |
|
|
2021
Q4 | $36.6M | Buy |
239,547
+66,364
| +38% | +$9.82M | ﹤0.01% | 2879 |
|
|
2021
Q3 | $23.5M | Sell |
173,183
-4,130
| -2% | -$565K | ﹤0.01% | 3173 |
|
|
2021
Q2 | $26M | Buy |
+177,313
| New | +$27.2M | ﹤0.01% | 3140 |
|
BlackRock's TRML Position: Q4 2025 in Review
BlackRock sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,517,777 shares — an estimated $72.6M sold.
BlackRock first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $72.6M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- BlackRock reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 1,517,777 Tourmaline Bio shares in Q4 2025, an estimated $72.6M.
- BlackRock first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- BlackRock's Tourmaline Bio position peaked at $72.6M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.